Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: A novel role for viral infection in tumor progression

FEMS Microbiology Reviews

Volumn 28, Issue 1, 2004, Pages 59-77

  Cinatl Jr , Jindrich ^a   Vogel, Jens Uwe ^a   Kotchetkov, Rouslan ^a   Doerr, Hans Wilhelm ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Angiogenesis; Apoptosis; DNA virus; Human cytomegalovirus; Oncomodulation; Tumor

Indexed keywords

ANGIOGENIC FACTOR; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; REGULATOR PROTEIN; VIRUS ANTIGEN; VIRUS PROTEIN;

ADENOVIRUS; ANGIOGENESIS; APOPTOSIS; CELL CYCLE; CELL INVASION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; DNA SYNTHESIS; DNA TUMOR VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOGENETICS; REVIEW; TUMOR GROWTH; VIRUS GENOME; VIRUS INFECTION; WART VIRUS;

DNA VIRUSES; HUMAN HERPESVIRUS 5; HUMAN PAPILLOMA VIRUS; PAPILLOMAVIRUS; TUMOR VIRUS;

EID: 1242351241     PISSN: 01686445     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.femsre.2003.07.005     Document Type: Review

References (163)

1. Giraldo G., Beth E., Henle W., Henle G., Mike V., Safai B., Huraux J.M., McHardy J., deThe G. Antibody patterns to herpesviruses in Kaposi's sarcoma. II. Serological association of American Kaposi's sarcoma with cytomegalovirus. Int. J. Cancer. 22:1978;126-131.
2. Giraldo G., Beth E., Huang E.S. Kaposi's sarcoma and its relationship to cytomegalovirus (CMNV). III. CMV DNA and CMV early antigens in Kaposi's sarcoma. Int. J. Cancer. 26:1980;23-29.
3. Boldogh I., Beth E., Huang E.S., Kyalwazi S.K., Giraldo G. Kaposi's sarcoma. IV. Detection of CMV DNA, CMV RNA and CMNA in tumor biopsies. Int. J. Cancer. 28:1981;469-474.
4. Huang E.S., Roche J.K. Cytomegalovirus D.N.A., adenocarcinoma of the colon: evidence for latent viral infection. Lancet. 1:1978;957-960.
5. Rüger R., Fleckenstein B. Cytomegalovirus DNA in colorectal carcinoma tissues. Klin. Wochenschr. 63:1985;405-408.
6. Sanford E.J., Geder L., Laychock A., Rohner T.J. Jr., Rapp F. Evidence for the association of cytomegalovirus with carcinoma of the prostate. J. Urol. 118:1977;789-792.
7. Boldogh I., Baskar J.F., Mar E.C., Huang E.S. Human cytomegalovirus and herpes simplex type 2 virus in normal and adenocarcinomatous prostate glands. J. Natl. Cancer Inst. 70:1983;819-826.
8. Pacsa A.S., Kummerlander L., Pejtsik B., Pali K. Herpesvirus antibodies and antigens in patients with cervical anaplasia and in controls. J. Natl. Cancer Inst. 55:1975;775-781.
9. Vestergaard B.F., Hornsleth A., Pedersen S.N. Occurrence of herpes- and adenovirus antibodies in patients with carcinoma of the cervix uteri. Measurement of antibodies to herpesvirus hominis (types 1 and 2), cytomegalovirus, EB-virus, and adenovirus. Cancer. 30:1972;68-74.
10. Fletcher K., Cordiner J.W., Macnab J.C. Detection of sequences that hybridize to human cytomegalovirus DNA in cervical neoplastic tissue. Dis. Markers. 4:1986;219-229.
11. Wertheim P., Voute P.A. Neuroblastoma, Wilms' tumor, and cytomegalovirus. J. Natl. Cancer Inst. 57:1976;701-703.
12. Nigro G., Schiavetti A., Booth J.C., Clerico A., Dominici C., Krzysztofiak A., Castello M. Cytomegalovirus-associated stage 4S neuroblastoma relapsed stage 4. Med. Pediatr. Oncol. 24:1995;200-203.
13. Huang G., Yan Q., Wang Z., Chen X., Zhang X., Guo Y., Li J.J. Human cytomegalovirus in neoplastic cells of Epstein-Barr virus negative Hodgkin's disease. Int. J. Oncol. 21:2002;31-36.
14. Harkins L., Volk A.L., Samanta M., Mikolaenko I., Britt W.J., Bland K.I., Cobbs C.S. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet. 360:2002;1557-1563.
15. Cobbs C.S., Harkins L., Samanta M., Gillespie G.Y., Bharara S., King P.H., Nabors L.B., Cobbs C.G., Britt W.J. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62:2002;3347-3350.
16. Cinatl J. Jr., Cinatl J., Vogel J.U., Rabenau H., Kornhuber B., Doerr H.W. Modulatory effects of human cytomegalovirus infection on malignant properties of cancer cells. Intervirology. 39:1996;259-269.
17. Fortunato E.A., McElroy A.K., Sanchez I., Spector D.H. Exploitation of cellular signaling and regulatory pathways by human cytomegalovirus. Trends Microbiol. 8:2000;111-119.
18. Scholz M., Doerr H.W., Cinatl J. Inhibition of cytomegalovirus immediate early gene expression: a therapeutic option? Antiviral Res. 49:2001;129-145.
19. Castillo J.P., Kowalik T.F. Human cytomegalovirus immediate early proteins and cell growth control. Gene. 290:2002;19-34.
20. Macnab J.C. Herpes simplex virus and human cytomegalovirus: their role in morphological transformation and genital cancers. J. Gen. Virol. 68:1987;2525-2550.
21. Shen Y., Zhu H., Shenk T. Human cytomagalovirus IE1 and IE2 proteins are mutagenic and mediate "hit-and-run" oncogenic transformation in cooperation with the adenovirus E1A proteins. Proc. Natl. Acad. Sci. USA. 94:1997;3341-3345.
22. Cinatl J. Jr., Cinatl J., Vogel J.U., Kotchetkov R., Driever P.H., Kabickova H., Kornhuber B., Schwabe D., Doerr H.W. Persistent human cytomegalovirus infection induces drug resistance and alteration of programmed cell death in human neuroblastoma cells. Cancer Res. 58:1998;367-372.
23. Henle W. (1971) Recent advances in tumour virology immunology. In: Proceedings of International Symposium. Princess Takamatsu Cancer Research Fund (Nakahara, S., Nishioka, K., Hirayama, T. and Ito, Y., Eds.), pp. 361-367. University Park Press, Baltimore, MD.
24. Ben Israel H., Kleinberger T. Adenovirus and cell cycle control. Front Biosci. 7:2002;d1369-d1395.
25. Finzer P., Aguilar-Lemarroy A., Rösl F. The role of human papillomavirus oncoproteins E6 and E7 in apoptosis. Cancer Lett. 188:2002;15-24.
26. Lee C., Cho Y. Interactions of SV40 large T antigen and other viral proteins with retinoblastoma tumour suppressor. Rev. Med. Virol. 12:2002;81-92.
27. Helt A.M., Galloway D.A. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis. 24:2003;159-169.
28. Poma E.E., Kowalik T.F., Zhu L., Sinclair J.H., Huang E.S. The human cytomegalovirus IE1-72 protein interacts with the cellular p107 protein and relieves p107-mediated transcriptional repression of an E2F-responsive promoter. J. Virol. 70:1996;7867-7877.
29. Hagemeier C., Caswell R., Hayhurst G., Sinclair J., Kouzarides T. Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein. EMBO J. 13:1994;2897-2903.
30. Fortunato E.A., Sommer M.H., Yoder K., Spector D.H. Identification of domains within the human cytomegalovirus major immediate-early 86-kilodalton protein and the retinoblastoma protein required for physical and functional interaction with each other. J. Virol. 71:1997;8176-8185.
31. Kalejta R.F., Shenk T. Manipulation of the cell cycle by human cytomegalovirus. Front Biosci. 7:2002;d295-d306.
32. Kalejta R.F., Bechtel J.T., Shenk T. Human cytomegalovirus pp71 stimulates cell cycle progression by inducing the proteasome-dependent degradation of the retinoblastoma family of tumor suppressors. Mol. Cell Biol. 23:2003;1885-1895.
33. Kalejta R.F., Shenk T. The human cytomegalovirus UL82 gene product (pp71) accelerates progression through the G(1) phase of the cell cycle. J. Virol. 77:2003;3451-3459.
34. Kalejta R.F., Shenk T. Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc. Natl. Acad. Sci. USA. 100:2003;3263-3268.
35. Speir E., Modali R., Huang E.S., Leon M.B., Shawl F., Finkel T., Epstein S.E. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 265:1994;391-394.
36. Tsai H.L., Kou G.H., Chen S.C., Wu C.W., Lin Y.S. Human cytomegalovirus immediate-early protein IE2 tethers a transcriptional repression domain to p53. J. Biol. Chem. 271:1996;3534-3540.
37. Chen Z., Knutson E., Kurosky A., Albrecht T. Degradation of p21cip1 in cells productively infected with human cytomegalovirus. J. Virol. 75:2001;3613-3625.
38. Doniger J., Muralidhar S., Rosenthal L.J. Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate. Clin. Microbiol. Rev. 12:1999;367-382.
39. Thompson J., Doniger J., Rosenthal L.J. A 79 amino acid oncogene is responsible for human cytomegalovirus mtrII induced malignant transformation. Arch. Virol. 136:1994;161-172.
40. Boldogh I., AbuBakar S., Albrecht T. Activation of proto-oncogenes: an immediate early event in human cytomegalovirus infection. Science. 247:1990;561-564.
41. Bresnahan W.A., Albrecht T., Thompson E.A. The cyclin E promoter is activated by human cytomegalovirus 86-kDa immediate early protein. J. Biol. Chem. 273:1998;22075-22082.
42. Wade M., Kowalik T.F., Mudryj M., Huang E.S., Azizkhan J.C. E2F mediates dihydrofolate reductase promoter activation and multiprotein complex formation in human cytomegalovirus infection. Mol. Cell Biol. 12:1992;4364-4374.
43. Hayhurst G.P., Bryant L.A., Caswell R.C., Walker S.M., Sinclair J.H. CCAAT box-dependent activation of the TATA-less human DNA polymerase alpha promoter by the human cytomegalovirus 72-kilodalton major immediate-early protein. J. Virol. 69:1995;182-188.
44. Bresnahan W.A., Boldogh I., Chi P., Thompson E.A., Albrecht T. Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication. Virology. 231:1997;239-247.
45. Jault F.M., Jault J.M., Ruchti F., Fortunato E.A., Clark C., Corbeil J., Richman D.D., Spector D.H. Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. J. Virol. 69:1995;6697-6704.
46. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 12:1998;2245-2262.
47. Song Y.J., Stinski M.F. Effect of the human cytomegalovirus IE86 protein on expression of E2F-responsive genes: a DNA microarray analysis. Proc. Natl. Acad. Sci. USA. 99:2002;2836-2841.
48. Bresnahan W.A., Boldogh I., Thompson E.A., Albrecht T. Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1. Virology. 224:1996;150-160.
49. Lu M., Shenk T. Human cytomegalovirus infection inhibits cell cycle progression at multiple points, including the transition from G1 to S. J. Virol. 70:1996;8850-8857.
50. Castillo J.P., Yurochko A.D., Kowalik T.F. Role of human cytomegalovirus immediate-early proteins in cell growth control. J. Virol. 74:2000;8028-8037.
51. Wiebusch L., Hagemeier C. Human cytomegalovirus 86-kilodalton IE2 protein blocks cell cycle progression in G(1). J. Virol. 73:1999;9274-9283.
52. Noris E., Zannetti C., Demurtas A., Sinclair J., De Andrea M., Gariglio M., Landolfo S. Cell cycle arrest by human cytomegalovirus 86-kDa IE2 protein resembles premature senescence. J. Virol. 76:2002;12135-12148.
53. Schmitt C.A. Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nat. Rev. Cancer. 3:2003;286-295.
54. Hayashi M.L., Blankenship C., Shenk T. Human cytomegalovirus UL69 protein is required for efficient accumulation of infected cells in the G1 phase of the cell cycle. Proc. Natl. Acad. Sci. USA. 97:2000;2692-2696.
55. Wiebusch L., Uecker R., Hagemeier C. Human cytomegalovirus prevents replication licensing by inhibiting MCM loading onto chromatin. EMBO Rep. 4:2003;42-46.
56. Biswas N., Sanchez V., Spector D.H. Human cytomegalovirus infection leads to accumulation of geminin and inhibition of the licensing of cellular DNA replication. J. Virol. 77:2003;2369-2376.
57. Lei M., Tye B.K. Initiating DNA synthesis: from recruiting to activating the MCM complex. J. Cell Sci. 114:2001;1447-1454.
58. Bell S.P., Dutta A. DNA replication in eukaryotic cells. Annu. Rev. Biochem. 71:2002;333-374.
59. Laskey R.A., Madine M.A. A rotary pumping model for helicase function of MCM proteins at a distance from replication forks. EMBO Rep. 4:2003;26-30.
60. Wiebusch, L. and Hagemeier, C. (2003) Taking away the replication license - HCMV and its impact on cellular DNA synthesis. In: New Aspects of CMV-Related Immunopathology. Monographs in Virology (Prösch, S., Cinatl Jr., J. and Scholz, M., Eds.), vol. 24, pp. 105-112. Karger, Basel, Switzerland.
61. Furukawa T. A variant of human cytomegalovirus derived from a persistently infected culture. Virology. 137:1984;191-194.
62. Ogura T., Tanaka J., Kamiya S., Sato H., Ogura H., Hatano M. Human cytomegalovirus persistent infection in a human central nervous system cell line: production of a variant virus with different growth characteristics. J. Gen. Virol. 67:1986;2605-2616.
63. Bonin L.R., McDougall J.K. Human cytomegalovirus IE2 86-kilodalton protein binds p53 but does not abrogate G1 checkpoint function. J. Virol. 71:1997;5861-5870.
64. Murphy E.A., Streblow D.N., Nelson J.A., Stinski M.F. The human cytomegalovirus IE86 protein can block cell cycle progression after inducing transition into the S phase of permissive cells. J. Virol. 74:2000;7108-7118.
65. Barrasa M.I., Harel N., Yu Y., Alwine J.C. Strain variations in single amino acids of the 86-kilodalton human cytomegalovirus major immediate-early protein (IE2) affect its functional and biochemical properties: implications of dynamic protein conformation. J. Virol. 77:2003;4760-4772.
66. Shreeram S., Sparks A., Lane D.P., Blow J.J. Cell type-specific responses of human cells to inhibition of replication licensing. Oncogene. 21:2002;6624-6632.
67. Wohlschlegel J.A., Kutok J.L., Weng A.P., Dutta A. Expression of geminin as a marker of cell proliferation in normal tissues and malignancies. Am. J. Pathol. 161:2002;267-273.
68. Spiller O.B., Borysiewicz L.K., Morgan B.P. Development of a model for cytomegalovirus infection of oligodendrocytes. J. Gen. Virol. 78:1997;3349-3356.
69. Jault F.M., Spector S.A., Spector D.H. The effects of cytomegalovirus on human immunodeficiency virus replication in brain-derived cells correlate with permissiveness of the cells for each virus. J. Virol. 68:1994;959-973.
70. Poland S.D., Costello P., Dekaban G.A., Rice G.P. Cytomegalovirus in the brain: in vitro infection of human brain-derived cells. J. Infect. Dis. 162:1990;1252-1262.
71. Murphy J.C., Fischle W., Verdin E., Sinclair J.H. Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J. 21:2002;1112-1120.
72. Caron C., Col E., Khochbin S. The viral control of cellular acetylation signaling. Bioassays. 25:2003;58-65.
73. Milutinovic S., Zhuang Q., Szyf M. Proliferating cell nuclear antigen associates with histone deacetylase activity, integrating DNA replication and chromatin modification. J. Biol. Chem. 277:2002;20974-20978.
74. Zhang Z.K., Davies K.P., Allen J., Zhu L., Pestell R.G., Zagzag D., Kalpana G.V. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol. Cell Biol. 22:2002;5975-5988.
75. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer. 1:2001;194-202.
76. Fortunato E.A., Sanchez V., Yen J.Y., Spector D.H. Infection of cells with human cytomegalovirus during S phase results in a blockade to immediate-early gene expression that can be overcome by inhibition of the proteasome. J. Virol. 76:2002;5369-5379.
77. Salvant B.S., Fortunato E.A., Spector D.H. Cell cycle dysregulation by human cytomegalovirus: influence of the cell cycle phase at the time of infection and effects on cyclin transcription. J. Virol. 72:1998;3729-3741.
78. Benedict C.A., Banks T.A., Senderowicz L., Ko M., Britt W.J., Angulo A., Ghazal P., Ware C.F. Lymphotoxins and cytomegalovirus cooperatively induce interferon-beta, establishing host-virus detente. Immunity. 15:2001;617-626.
79. Browne E.P., Wing B., Coleman D., Shenk T. Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: viral block to the accumulation of antiviral mRNAs. J. Virol. 75:2001;12319-12330.
80. Benedict C.A., Norris P.S., Ware C.F. To kill or be killed: viral evasion of apoptosis. Nat. Immunol. 3:2002;1013-1018.
81. White E. Regulation of apoptosis by adenovirus E1A and E1B oncogenes. Semin. Virol. 8:1998;505-513.
82. Westbrook T.F., Nguyen D.X., Thrash B.R., McCance D.J. E7 abolishes raf-induced arrest via mislocalization of p21(Cip1). Mol. Cell Biol. 22:2002;7041-7052.
83. Dahl J., Jurczak A., Cheng L.A., Baker D.C., Benjamin T.L. Evidence of a role for phosphatidylinositol 3-kinase activation in the blocking of apoptosis by polyomavirus middle T antigen. J. Virol. 72:1998;3221-3226.
84. Tanaka K., Zou J.P., Takeda K., Ferrans V.J., Sandford G.R., Johnson T.M., Finkel T., Epstein S.E. Effects of human cytomegalovirus immediate-early proteins on p53-mediated apoptosis in coronary artery smooth muscle cells. Circulation. 99:1999;1656-1659.
85. Lukac D.M., Alwine J.C. Effects of human cytomegalovirus major immediate-early proteins in controlling the cell cycle and inhibiting apoptosis: studies with ts13 cells. J. Virol. 73:1999;2825-2831.
86. Zhu H., Shen Y., Shenk T. Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J. Virol. 69:1995;7960-7970.
87. Pari G.S., Anders D.G. Eleven loci encoding trans-acting factors are required for transient complementation of human cytomegalovirus oriLyt-dependent DNA replication. J. Virol. 67:1993;6979-6988.
88. Skaletskaya A., Bartle L.M., Chittenden T., McCormick A.L., Mocarski E.S., Goldmacher V.S. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc. Natl. Acad. Sci. USA. 98:2001;7829-7834.
89. Goldmacher V.S., Bartle L.M., Skaletskaya A., Dionne C.A., Kedersha N.L., Vater C.A., Han J.W., Lutz R.J., Watanabe S., Cahir McFarland E.D., Kieff E.D., Mocarski E.S., Chittenden T. A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2. Proc. Natl. Acad. Sci. USA. 96:1999;12536-12541.
90. Hayajneh W.A., Colberg-Poley A.M., Skaletskaya A., Bartle L.M., Lesperance M.M., Contopoulos-Ioannidis D.G., Kedersha N.L., Goldmacher V.S. The sequence and antiapoptotic functional domains of the human cytomegalovirus UL37 exon 1 immediate early protein are conserved in multiple primary strains. Virology. 279:2001;233-240.
91. Goldmacher V.S. vMIA, a viral inhibitor of apoptosis targeting mitochondria. Biochimie. 84:2002;177-185.
92. Cinatl J. Jr., Blaheta R., Bittoova M., Scholz M., Margraf S., Vogel J.-U., Cinatl J., Doerr H.W. Decreased neutrophil adhesion to human cytomegalovirus-infected retinal pigment epithelial cells is mediated by virus-induced up-regulation of Fas ligand independent of neutrophil apoptosis. J. Immunol. 165:2000;4405-4413.
93. Chiou S.H., Liu J.H., Hsu W.M., Chen S.S., Chang S.Y., Juan L.J., Lin J.C., Yang Y.T., Wong W.W., Liu C.Y., Lin Y.S., Liu W.T., Wu C.W. Up-regulation of Fas ligand expression by human cytomegalovirus immediate-early gene product 2: a novel mechanism in cytomegalovirus-induced apoptosis in human retina. J. Immunol. 167:2001;4098-4103.
94. Sedger L.M., Shows D.M., Blanton R.A., Peschon J.J., Goodwin R.G., Cosman D., Wiley S.R. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J. Immunol. 163:1999;920-926.
95. Benedict C.A., Butrovich K.D., Lurain N.S., Corbeil J., Rooney I., Schneider P., Tschopp J., Ware C.F. Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J. Immunol. 162:1999;6967-6970.
96. Smith C.A., Davis T., Anderson D., Solam L., Beckmann M.P., Jerzy R., Dower S.K., Cosman D., Goodwin R.G. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science. 248:1990;1019-1023.
97. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev. 13:1999;2905-2927.
98. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2:2002;489-501.
99. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:1997;231-241.
100. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., Frisch S., Reed J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science. 282:1998;1318-1321.
101. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 96:1999;857-868.
102. Johnson R.A., Wang X., Ma X.L., Huong S.M., Huang E.S. Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J. Virol. 75:2001;6022-6032.
103. Yu Y., Alwine J.C. Human cytomegalovirus major immediate-early proteins and simian virus 40 large T antigen can inhibit apoptosis through activation of the phosphatidylinositide. 3′ -OH kinase pathway and the cellular kinase Akt J. Virol. 76:2002;3731-3738.
104. Itoh N., Semba S., Ito M., Takeda H., Kawata S., Yamakawa M. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer. 94:2002;3127-3134.
105. Moll U.M., Erster S., Zaika A. p53, p63 and p73 - solos, alliances and feuds among family members. Biochim. Biophys. Acta. 1552:2001;47-59.
106. Melino G., De L., Vand Vousden K.H. p73: friend or foe in tumorigenesis. Nat. Rev. Cancer. 2:2002;605-615.
107. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 416:2002;560-564.
108. Dobbelstein M., Roth J. The large T antigen of simian virus 40 binds and inactivates p53 but not p73. J. Gen. Virol. 79(Pt 12):1998;3079-3083.
109. Marin M.C., Jost C.A., Irwin M.S., DeCaprio J.A., Caput D., Kaelin W.G. Jr. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol. Cell Biol. 18:1998;6316-6324.
110. Allart S., Martin H., Detraves C., Terrasson J., Caput D., Davrinche C. Human cytomegalovirus induces drug resistance and alteration of programmed cell death by accumulation of deltaN-p73alpha. J. Biol. Chem. 277:2002;29063-29068.
111. Casciano I., Mazzocco K., Boni L., Pagnan G., Banelli B., Allemanni G., Ponzoni M., Tonini G.P., Romani M. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 9:2002;246-251.
112. Makin G., Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol. 11:2001;S22-S26.
113. Cory S., Adams J.M. The Bcl-2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer. 2:2002;647-656.
114. Martinou J.C., Green D.R. Breaking the mitochondrial barrier. Nat. Rev. Mol. Cell Biol. 2:2001;63-67.
115. Zamzami N., Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat. Rev. Mol. Cell Biol. 2:2001;67-71.
116. Billstrom Schroeder M., Christensen R., Worthen G.S. Human cytomegalovirus protects endothelial cells from apoptosis induced by growth factor withdrawal. J. Clin. Virol. 25:2002;S149-S157.
117. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
118. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer. 2:2002;727-739.
119. Folkman J., Browder T., Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb. Haemost. 86:2001;23-33.
120. Rak J., Yu J.L., Klement G., Kerbel R.S. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J. Investig. Dermatol. Symp. Proc. 5:2000;24-33.
121. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R., Moghaddam A., Whitehouse R., Bicknell R., Harris A.L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57:1997;963-969.
122. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., Moons L., Jain R.K., Collen D., Keshert E., Keshet E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:1998;485-490.
123. Rafii S., Lyden D., Benezra R., Hattori K., Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy. Nat. Rev. Cancer. 2:2002;826-835.
124. Arbeit J.M., Olson D.C., Hanahan D. Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice. Oncogene. 13:1996;1847-1857.
125. Bequet-Romero M., Lopez-Ocejo O. Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins. Biochem. Biophys. Res. Commun. 277:2000;55-61.
126. Lopez-Ocejo O., Viloria-Petit A., Bequet-Romero M., Mukhopadhyay D., Rak J., Kerbel R.S. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene. 19:2000;4611-4620.
127. Stöppler H., Malerczyk C., Block K., Aigner A., Czubayko F. The human papillomavirus (HPV) 16 E6 oncoprotein leads to an increase in gene expression of the angiogenic switch molecule FGF-BP in non-immortalized human keratinocytes. Oncogene. 20:2001;7430-7436.
128. Catalano A., Romano M., Martinotti S., Procopio A. Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen. Oncogene. 21:2002;2896-2900.
129. Sherif Z.A., Nakai S., Pirollo K.F., Rait A., Chang E.H. Downmodulation of bFGF-binding protein expression following restoration of p53 function. Cancer Gene Ther. 8:2001;771-782.
130. Yu J.L., Rak J.W., Coomber B.L., Hicklin D.J., Kerbel R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science. 295:2002;1526-1528.
131. Penfold M.E., Dairaghi D.J., Duke G.M., Saederup N., Mocarski E.S., Kemble G.W., Schall T.J. Cytomegalovirus encodes a potent alpha chemokine. Proc. Natl. Acad. Sci. USA. 96:1999;9839-9844.
132. Addison C.L., Daniel T.O., Burdick M.D., Liu H., Ehlert J.E., Xue Y.Y., Buechi L., Walz A., Richmond A., Strieter R.M. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J. Immunol. 165:2000;5269-5277.
133. Inoue K., Slaton J.W., Eve B.Y., Kim S.J., Perrotte P., Balbay M.D., Yano S., Bar-Eli M., Radinsky R., Pettaway C.A., Dinney C.P. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin. Cancer Res. 6:2000;2104-2119.
134. Li A., Varney M.L., Singh R.K. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin. Cancer Res. 7:2001;3298-3304.
135. Dhawan P., Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol. 72:2002;9-18.
136. Alcami J., Barzu T., Michelson S. Induction of an endothelial cell growth factor by human cytomegalovirus infection of fibroblasts. J. Gen. Virol. 72:1991;2765-2770.
137. St. Jeor, S., Admiraud, J., Bruening, E. and Riolo, J. (1993) Induction of cytokines by human cytomegalovirus. In: Multidisciplinary Approach to Understanding Cytomegalovirus Disease (Michelson, S. and Plotkin, S.A., Eds.), pp. 123-126. Elsevier, Amsterdam.
138. Lagneaux L., Delforge A., Snoeck R., Bosmans E., Schols D., De Clereq E., Stryckmans P., Bron D. Imbalance in production of cytokines by bone marrow stromal cells following cytomegalovirus infection. J. Infect. Dis. 174:1996;913-919.
139. Michelson S., Alcami J., Kim S.J., Danielpour D., Bachelerie F., Picard L., Bessia C., Paya C., Virelizier J.L. Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1. J. Virol. 68:1994;5730-5737.
140. Geist L.J., Hopkins H.A., Dai L.Y., He B., Monick M.M., Hunninghake G.W. Cytomegalovirus modulates transcription factors necessary for the activation of the tumor necrosis factor-alpha promoter. Am. J. Respir. Cell Mol. Biol. 16:1997;31-37.
141. Crump J.W., Geist L.J., Auron P.E., Webb A.C., Stinski M.F., Hunninghake G.W. The immediate early genes of human cytomegalovirus require only proximal promoter elements to upregulate expression of interleukin-1 beta. Am. J. Respir. Cell Mol. Biol. 6:1992;674-677.
142. Carlquist J.F., Edelman L., Bennion D.W., Anderson J.L. Cytomegalovirus induction of interleukin-6 in lung fibroblasts occurs independently of active infection and involves a G protein and the transcription factor, NF-kappaB. J. Infect. Dis. 179:1999;1094-1100.
143. Cinatl J. Jr., Kotchetkov R., Weimer E., Blaheta R.A., Scholz M., Vogel J.-U., Gumbel H.O., Doerr H.W. The antisense oligonucleotide ISIS 2922 prevents cytomegalovirus-induced upregulation of IL-8 and ICAM-1 in cultured human fibroblasts. J. Med. Virol. 60:2000;313-323.
144. Grundy J.E., Lawson K.M., MacCormac L.P., Fletcher J.M., Yong K.L. Cytomegalovirus-infected endothelial cells recruit neutrophils by the secretion of C-X-C chemokines and transmit virus by direct neutrophil-endothelial cell contact and during neutrophil transendothelial migration. J. Infect. Dis. 177:1998;1465-1474.
145. Speir E., Yu Z.X., Ferrans V.J., Huang E.S., Epstein S.E. Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circ. Res. 83:1998;210-216.
146. Yoo Y.D., Chiou C.J., Choi K.S., Yi Y., Michelson S., Kim S., Hayward G.S., Kim S.J. The IE2 regulatory protein of human cytomegalovirus induces expression of the human transforming growth factor beta1 gene through an Egr-1 binding site. J. Virol. 70:1996;7062-7070.
147. Murayama T., Mukaida N., Sadanari H., Yamaguchi N., Khabar K.S., Tanaka J., Matsushima K., Mori S., Eizuru Y. The immediate early gene 1 product of human cytomegalovirus is sufficient for up-regulation of interleukin-8 gene expression. Biochem. Biophys. Res. Commun. 279:2000;298-304.
148. Cinatl J. Jr., Kotchetkov R., Scholz M., Cinatl J., Vogel J.-U., Driever P.H., Doerr H.W. Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53. Am. J. Pathol. 155:1999;285-292.
149. Cinatl J. Jr., Bittoova M., Margraf S., Vogel J.-U., Cinatl J., Preiser W., Doerr H.W. Cytomegalovirus infection decreases expression of thrombospondin-1 and -2 in cultured human retinal glial cells: effects of antiviral agents. J. Infect. Dis. 182:2000;643-651.
150. Streit M., Riccardi L., Velasco P., Brown L.F., Hawighorst T., Bornstein P., Detmar M. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc. Natl. Acad. Sci. USA. 96:1999;14888-14893.
151. Kazuno M., Tokunaga T., Oshika Y., Tanaka Y., Tsugane R., Kijima H., Yamazaki H., Ueyama Y., Nakamura M. Thrombospondin-2 (TSP2) expression is inversely correlated with vascularity in glioma. Eur. J. Cancer. 35:1999;502-506.
152. Maeda K., Nishiguchi Y., Kang S.M., Yashiro M., Onoda N., Sawada T., Ishikawa T., Hirakawa K. Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer. Oncol. Rep. 8:2001;763-766.
153. Maisch T., Kropff B., Sinzger C., Mach M. Upregulation of CD40 expression on endothelial cells infected with human cytomegalovirus. J. Virol. 76:2002;12803-12812.
154. Calderhead D.M., Kosaka Y., Manning E.M., Noelle R.J. CD40-CD154 interactions in B-cell signaling. Curr. Top. Microbiol. Immunol. 245:2000;73-99.
155. Grewal I.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16:1998;111-135.
156. van Kooten C., Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr. Opin. Immunol. 9:1997;330-337.
157. Guzman-Rojas L., Sims-Mourtada J.C., Rangel R., Martinez-Valdez H. Life and death within germinal centres: a double-edged sword. Immunology. 107:2002;167-175.
158. Lutgens E., Gorelik L., Daemen M.J., de Muinck E.D., Grewal I.S., Koteliansky V.E., Flavell R.A. Requirement for CD154 in the progression of atherosclerosis. Nat. Med. 5:1999;1313-1316.
159. Tai Y.T., Podar K., Gupta D., Lin B., Young G., Akiyama M., Anderson K.C. CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood. 99:2002;1419-1427.
160. Biancone L., Cantaluppi V., Boccellino M., Del Sorbo L., Russo S., Albini A., Stamenkovic I., Camussi G. Activation of CD40 favors the growth and vascularization of Kaposi's sarcoma. J. Immunol. 163:1999;6201-6208.
161. Melter M., Reinders M.E., Sho M., Pal S., Geehan C., Denton M.D., Mukhopadhyay D., Briscoe D.M. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood. 96:2000;3801-3808.
162. Cho C.S., Cho M.L., Min S.Y., Kim W.U., Min D.J., Lee S.S., Park S.H., Choe J., Kim H.Y. CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor. J. Immunol. 164:2000;5055-5061.
163. Herne K.L., Talpur R., Breuer-McHam J., Champlin R., Duvic M. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome. Blood. 101:2003;2132-2136.